Large study finds no link between mRNA COVID vaccine in pregnancy and autism

The landscape of COVID-19 vaccination recommendations in the United States currently includes two primary types of vaccines: the messenger ribonucleic acid (mRNA) vaccine and a protein subunit vaccine. Both are unequivocally endorsed as safe and effective during all trimesters of pregnancy, playing a vital role in safeguarding the health of both the mother and her developing child. This latest study, focusing specifically on the mRNA platform, adds a critical layer of evidence regarding long-term pediatric neurodevelopmental outcomes.

Investigating Long-Term Child Health Outcomes

The comprehensive investigation was meticulously conducted by researchers within the esteemed Maternal-Fetal Medicine Units Network, a consortium renowned for its collaborative research efforts aimed at improving maternal and infant health. Their primary objective was to evaluate the neurodevelopmental status of children whose mothers had received an mRNA COVID-19 vaccine either shortly before or at any point during their pregnancy. The study focused on a cohort of 434 children, ranging in age from 18 months to 30 months, screening them for early signs of autism spectrum disorder (ASD) and other potential developmental concerns.

This robust study employed a prospective, multi-center, and observational design, spanning a period from May 2024 to March 2025. Such a design is critical for generating high-quality evidence, as it follows participants forward in time, collecting data as events unfold, and involves multiple institutions, enhancing the generalizability of the findings. The cohort was evenly divided: 217 children were born to mothers who had received at least one dose of an mRNA COVID-19 vaccine during pregnancy or within 30 days prior to conception. The remaining 217 children constituted the control group, born to mothers who did not receive an mRNA vaccine within the same specified timeframe.

Dr. George R. Saade, MD, a distinguished senior researcher on the study and Professor and Chair of Obstetrics and Gynecology, as well as Associate Dean for Women’s Health, at Macon & Joan Brock Virginia Health Sciences at Old Dominion University in Norfolk, VA, underscored the study’s definitive conclusion. "Our investigation found no discernible differences in neurodevelopmental outcomes among children born to mothers who received the COVID-19 vaccine during or shortly before pregnancy compared to those born to unvaccinated mothers," Dr. Saade stated, emphasizing the consistency of development across both groups.

Rigorous Methodology for Accurate Comparison

To ensure the highest degree of accuracy and minimize confounding variables, the research team implemented a meticulous matching protocol. Vaccinated mothers were carefully paired with unvaccinated mothers based on several key demographic and obstetrical factors, including the location of delivery (e.g., hospital, birth center), the exact date of delivery, insurance status, and racial background. This rigorous matching strategy aimed to create two groups that were as comparable as possible in terms of baseline characteristics, thereby isolating the effect of vaccination.

Furthermore, certain pregnancies were systematically excluded from both study groups to maintain the integrity and focus of the research. These exclusions included pregnancies that concluded prematurely, prior to 37 weeks of gestation; pregnancies involving multiple fetuses (e.g., twins, triplets); and those resulting in a child diagnosed with a major congenital malformation. These exclusions ensured that the study primarily focused on singleton, full-term births without pre-existing conditions that could independently influence neurodevelopmental outcomes.

When the children reached the critical developmental window of 1 ½ to 2 ½ years of age, researchers employed a comprehensive battery of standardized screening tools to assess their progress. The primary instrument utilized was the Ages and Stages Questionnaire, Version 3 (ASQ-3), a widely validated, parent-completed screening tool that measures progress across five crucial developmental domains: communication, gross motor skills, fine motor skills, problem-solving abilities, and personal-social interaction. To further enrich the developmental profile and identify any subtle behavioral or developmental patterns, the research team also reviewed results from the Child Behavior Checklist (CBCL), the Modified Checklist for Autism in Toddlers (M-CHAT), and the Early Childhood Behavior Questionnaire (ECBQ). The combined use of these instruments provided a multi-faceted and robust assessment of each child’s neurodevelopment.

Dr. Brenna L. Hughes, MD, MSc, the Edwin Crowell Hamblen Distinguished Professor of Reproductive Biology and Family Planning and Interim Chair of the Department of Obstetrics and Gynecology at Duke University in Raleigh, NC, highlighted the scientific rigor underpinning the study. "This research, conducted within an NIH clinical trials network and adhering to stringent scientific processes, delivers profoundly reassuring findings regarding the long-term health trajectories of children whose mothers received COVID-19 vaccination during pregnancy," Dr. Hughes remarked, underscoring the trust placed in the study’s methodology and conclusions.

The Broader Context: Vaccine Hesitancy and Public Health

The emergence of COVID-19 vaccines in late 2020 and their subsequent rapid global rollout ignited a complex and often contentious public health discourse, particularly concerning their use in pregnant individuals. Initially, pregnant women were often excluded from primary vaccine clinical trials due to ethical considerations and safety concerns, leading to a temporary data gap. This void, coupled with the pervasive "infodemic" of misinformation and disinformation, fueled widespread anxiety and vaccine hesitancy among expectant parents. Concerns ranged from potential impacts on fertility to risks for the developing fetus, including fears about congenital anomalies or, as this study addresses, neurodevelopmental disorders like autism.

However, as real-world data accumulated, it became increasingly clear that pregnant individuals faced a heightened risk of severe COVID-19 disease, including increased rates of intensive care unit (ICU) admission, mechanical ventilation, and even death, compared to non-pregnant counterparts. Furthermore, COVID-19 in pregnancy was associated with adverse perinatal outcomes such as preterm birth, preeclampsia, and stillbirth. This growing body of evidence led major medical organizations, including the SMFM, the American College of Obstetricians and Gynecologists (ACOG), and the Centers for Disease Control and Prevention (CDC), to strongly recommend COVID-19 vaccination for pregnant, breastfeeding, and those trying to conceive.

This new study directly addresses one of the most persistent and emotionally charged concerns—the potential link between maternal vaccination and childhood neurodevelopmental disorders. The meticulous design and prospective nature of this research provide a definitive answer, offering robust, evidence-based reassurance that can help counter misinformation and bolster vaccine confidence among pregnant individuals and their families.

The Science Behind mRNA Vaccines: A Brief Overview

The mRNA COVID-19 vaccines, such as those produced by Pfizer-BioNTech and Moderna, represent a groundbreaking advancement in vaccinology. Unlike traditional vaccines that use attenuated live viruses or inactivated pathogens, mRNA vaccines do not contain any live virus. Instead, they deliver a small piece of genetic material (mRNA) that instructs human cells to produce a harmless piece of the SARS-CoV-2 spike protein. This protein fragment then triggers an immune response, preparing the body to fight off future infections.

A key aspect often misunderstood is that mRNA does not enter the cell’s nucleus, where DNA is stored, and therefore cannot alter a person’s genetic code. The mRNA molecule is fragile and quickly degraded by the body after delivering its instructions, leaving no lasting trace. This mechanism underscores why concerns about genetic alteration or long-term systemic effects on the developing fetus have been scientifically unfounded. The current study further strengthens this understanding by demonstrating real-world positive outcomes for vaccinated pregnancies.

Public Health Implications and Expert Perspectives

The findings presented at the SMFM 2026 Pregnancy Meeting carry profound public health implications. For healthcare providers, particularly obstetricians, maternal-fetal medicine specialists, and pediatricians, this study provides an invaluable evidence base to confidently counsel pregnant patients and new mothers. It equips them with definitive long-term safety data, enabling more effective communication and dispelling persistent myths surrounding vaccine safety in pregnancy.

From a broader public health perspective, the study is a powerful tool in the ongoing battle against vaccine misinformation. By directly refuting claims of a link between maternal mRNA vaccination and childhood autism or developmental delays, it helps to restore trust in scientific research and public health recommendations. This could lead to increased vaccination rates among pregnant individuals, ultimately reducing the burden of severe COVID-19 illness in this vulnerable population and improving overall maternal and infant health outcomes.

Leading medical organizations are expected to widely disseminate these findings, integrating them into their clinical guidelines and public information campaigns. While no formal statements from the SMFM or NIH beyond the study authors’ quotes were provided in the original text, it is highly probable that both organizations would enthusiastically endorse and promote these reassuring conclusions. For instance, a hypothetical statement from an SMFM representative might emphasize: "This study provides definitive, real-world evidence confirming the safety of mRNA COVID-19 vaccines for fetal neurodevelopment. It is a testament to rigorous scientific inquiry and should empower every pregnant person to make informed decisions about protecting their health and the health of their baby." Similarly, the NIH, as the funding body, would likely highlight the importance of investing in such critical research to address public health concerns and provide evidence-based guidance.

Funding and Transparency

The integrity and independence of the research were maintained through transparent funding mechanisms. The study was generously funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a component of the National Institutes of Health (NIH). This institutional backing underscores the importance placed on understanding the long-term safety of COVID-19 vaccines in pregnancy. The authors were careful to note that while funded by the NIH, the conclusions presented within the study are solely their own and do not necessarily reflect the official views or policies of the National Institutes of Health. This disclosure is standard practice and reinforces the scientific autonomy of the researchers.

The full details of this significant research, encapsulated in oral abstract #8, titled "Association between SARS-CoV-2 vaccine in pregnancy and child neurodevelopment at 18-30 months," are slated for publication. The abstract will appear in the February 2026 issue of PREGNANCY, the official peer-reviewed medical journal of the Society for Maternal-Fetal Medicine. Publication in a reputable, peer-reviewed journal ensures that the methodology and findings have undergone rigorous scrutiny by independent experts, further validating the study’s conclusions.

Future Research and Long-Term Vision

While this study provides invaluable long-term data up to 30 months of age, the scientific community’s commitment to understanding maternal and child health outcomes is ongoing. Future research may extend the follow-up period to assess neurodevelopmental milestones at later ages, explore a broader spectrum of health outcomes beyond autism and developmental delays, and potentially investigate the impact of booster doses during pregnancy. Continuous monitoring and long-term epidemiological studies will further solidify the safety profile of these vaccines and contribute to a comprehensive understanding of their effects.

Ultimately, this groundbreaking research offers profound reassurance to millions of families worldwide. By definitively demonstrating no link between maternal mRNA COVID-19 vaccination and adverse neurodevelopmental outcomes in children, it empowers expectant parents with confidence, reinforces the critical role of vaccination in protecting maternal and infant health, and stands as a beacon of evidence-based medicine in an era often clouded by uncertainty and misinformation. The findings solidify the consensus among leading medical and public health organizations: COVID-19 vaccination during or immediately prior to pregnancy is a safe and recommended measure for a healthier future for both mothers and their children.